Interview with Craig Moore, Director, Hahn Healthcare
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Address: Level 3 21 Solent Circuit BAULKHAM HILLS NSW 2153 AUSTRALIA
,Australia
Tel: 1800 224 321
Web: http://www.novonordisk.com.au/documents/home_page/document/index.asp
At Novo Nordisk, we strive to be the world’s leading diabetes care company, and each of us takes this vision personally. Our highest priority is the health and well being of people living with diabetes. We respect their many lifestyles and individual needs and develop our therapies with those differences in mind.
Through intensive research, Novo Nordisk has created innovative insulin delivery systems as well as disposable needles that were designed to help reduce pain and fear of injection. Using recombinant technology, we have developed novel insulin and insulin analog formulations. We also offer patient education programs, continuing medical education for healthcare professionals, and more, as we strive to meet the individual needs of our customers!
In addition, we hold a leading position in other therapeutic areas, such as coagulation disorders, growth hormone disorders, and hormone therapy for women.
Novo Nordisk has affiliate offices in 81 countries and approximately 27,000 full-time employees worldwide. We reach out to 179 countries around the world with our products and programs. We operate manufacturing facilities in six countries, including the United States.
Novo Nordisk has a comprehensive range of products relating to diabetes, haemostasis, growth and the menopause.
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
“Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008.…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
Speaking to the Australian environment, how would you rate the market in terms of companies like Swisse? After traveling the world, the Australian market has shown to be one of…
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that…
The company underwent some landmark changes under your leadership, changing the balance between different pillars of the business – retail, wholesale product delivery, marketing programs. Would you begin by outlining…
After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and…
Can you start by commenting on the state of diabetes in Australia at present? According to 2011 statistics nearly one million Australians have diabetes and about half of those are…
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
See our Cookie Privacy Policy Here
